Get the Stockscreener App
1.58
2.47%
-0.04
After Hours:
1.58
Lava Therapeutics Nv stock is traded at $1.58, with a volume of 71,013.
It is down -2.47% in the last 24 hours and up +1.94% over the past month.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
See More
Previous Close:
$1.62
Open:
$1.62
24h Volume:
71,013
Relative Volume:
0.33
Market Cap:
$41.56M
Revenue:
$9.06M
Net Income/Loss:
$-50.39M
P/E Ratio:
-0.8229
EPS:
-1.92
Net Cash Flow:
$5.89M
1W Performance:
+2.60%
1M Performance:
+1.94%
6M Performance:
+39.82%
1Y Performance:
-3.66%
1-Day Range:
$1.56
$1.63
1-Week Range:
$1.54
$1.64
52-Week Range:
$0.8502
$2.093
Lava Therapeutics Nv Stock (LVTX) Company Profile
Name
Lava Therapeutics Nv
Sector
Industry
Phone
31 6 3000 3035
Address
YALELAAN 62, UTRECHT
Compare LVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
1.58 | 42.61M | 9.06M | -50.39M | 5.89M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-25-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-21 | Initiated | JP Morgan | Overweight |
| Apr-19-21 | Initiated | Jefferies | Buy |
| Apr-19-21 | Initiated | SVB Leerink | Outperform |
View All
Lava Therapeutics Nv Stock (LVTX) Latest News
Is LAVA Therapeutics N.V. forming a reversal patternLayoff News & Expert Approved Momentum Trade Ideas - newser.com
Is LAVA Therapeutics N.V. (4PKB) stock overpriced at current multiplesJuly 2025 Momentum & Low Drawdown Momentum Ideas - newser.com
Why LAVA Therapeutics N.V. stock remains resilientTrade Signal Summary & High Win Rate Trade Tips - newser.com
Published on: 2025-10-05 06:23:52 - newser.com
Analyzing recovery setups for LAVA Therapeutics N.V. investorsJuly 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - newser.com
Measuring LAVA Therapeutics N.V.’s beta against major indicesQuarterly Trade Report & High Conviction Investment Ideas - newser.com
Will LAVA Therapeutics N.V. outperform the marketJuly 2025 Setups & Entry Point Confirmation Signals - newser.com
What candlestick patterns are forming on LAVA Therapeutics N.V.Weekly Trend Recap & Daily Oversold Bounce Ideas - newser.com
How LAVA Therapeutics N.V. stock performs in rate cut cyclesJuly 2025 Catalysts & Fast Gaining Stock Strategy Reports - newser.com
Shay Capital LLC Acquires Significant Stake in LAVA Therapeutics NV - GuruFocus
LAVA Therapeutics Extends Tender Offer Deadline - TipRanks
XOMA Royalty extends tender offer deadline for LAVA Therapeutics By Investing.com - Investing.com Australia
XOMA Royalty extends tender offer deadline for LAVA Therapeutics - Investing.com India
XOMA Royalty Corporation Extends Tender Offer for LAVA Therapeutics Shares Until October 17, 2025 - Quiver Quantitative
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. - GlobeNewswire
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. - Benzinga
75% CVR: XOMA Royalty Extends Tender Offer for LAVA, Extended to Oct. 17 - Stock Titan
What drives LAVA Therapeutics NV stock priceBollinger Bands Signals & High-Risk, High-Reward? We Find the Winners - earlytimes.in
LAVA Therapeutics Postpones EGM for XOMA Deal - MSN
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025 - GlobeNewswire
LAVA Therapeutics Cancels Extraordinary General Meeting to Finalize XOMA Royalty Acquisition Details - Quiver Quantitative
Biotech Deal Update: LAVA Therapeutics Postpones XOMA Acquisition Vote to Address Cash Position - Stock Titan
Published on: 2025-09-26 19:58:52 - newser.com
Lava Therapeutics Nv Stock (LVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lava Therapeutics Nv Stock (LVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L. | 10% Owner |
Sep 19 '25 |
Sale |
1.40 |
532,870 |
746,764 |
0 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 17 '25 |
Sale |
1.49 |
362,806 |
540,291 |
2,736,644 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 18 '25 |
Sale |
1.44 |
366,111 |
527,859 |
2,370,533 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 16 '25 |
Sale |
1.53 |
307,707 |
471,776 |
3,099,450 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 17 '25 |
Sale |
1.49 |
226,726 |
337,640 |
761,661 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 18 '25 |
Sale |
1.44 |
228,791 |
329,871 |
532,870 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 16 '25 |
Sale |
1.53 |
192,293 |
294,824 |
988,387 |
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):